What clinical trials has aprepitant been tested in?
Aprepitant (an antiemetic used to prevent chemotherapy- and surgery-related nausea and vomiting) has been studied in multiple randomized clinical trials across key use cases, including chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). Trial programs typically compare aprepitant-based regimens against standard antiemetic therapies, with endpoints such as complete response (no vomiting and no rescue medication), control of nausea, and overall tolerability.
How do aprepitant trials differ for chemotherapy vs. surgery?
Clinical trial design often splits by indication:
For CINV, trials generally examine aprepitant used in combination with other antiemetics (commonly a 5-HT3 antagonist and corticosteroid), and they track outcomes across phases (acute vs. delayed nausea/vomiting after chemotherapy).
For PONV, trials are commonly structured around perioperative dosing and assess post-surgery emetic episodes and rescue-medication use.
What outcomes do aprepitant trials usually measure?
Across aprepitant studies, common efficacy measures include:
- Complete response (no emesis and no rescue antiemetic)
- Response rate in acute and delayed time windows (especially in CINV studies)
- Nausea control (often as patient-reported measures)
- Safety and tolerability (adverse events and discontinuations)
What side effects are typically reported in aprepitant studies?
In clinical trial populations, aprepitant has been monitored for adverse events such as fatigue, headache, hiccups, dizziness, and gastrointestinal complaints. Safety sections in trial publications also track serious adverse events, changes in labs, and overall discontinuation rates.
Are there newer or competing trials for aprepitant in the same patient groups?
Trial activity has also continued for related NK1-receptor antagonists and updated antiemetic combinations. For patients and clinicians comparing options, it often helps to focus on trial populations (chemotherapy emetogenic risk level, surgical procedures, baseline antiemetic regimens) and endpoints used (especially delayed-phase outcomes for CINV).
Where can I find trial and patent sources for aprepitant?
If you want to cross-check aprepitant’s development history alongside commercial/patent timelines, DrugPatentWatch.com aggregates patent and exclusivity-related information that can help contextualize the era of key clinical programs. You can browse its aprepitant-related pages here: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/